Rising Biosciences (Rising Biosciences) Current Accrued Expense : $0.00 Mil (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Current Accrued Expense?

Rising Biosciences's Current Accrued Expense for the quarter that ended in . 20 was $0.00 Mil.

Rising Biosciences Current Accrued Expense Historical Data

The historical data trend for Rising Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Current Accrued Expense Chart

Rising Biosciences Annual Data

Trend

Current Accrued Expense

Rising Biosciences Quarterly Data

Current Accrued Expense

Rising Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Rising Biosciences Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Current Accrued Expense

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.